CD19 and plasma cell myeloma: This was consistent with the findings of a recent study on the use of anti‐CD19 and anti‐BCMA CARs in vitro for primary tumor cells from myeloma patients, which showed a consistent, significant reduction in myeloma‐propagating capability.22